Skip to main content

Rabbit Recombinant Monoclonal Cytochrome P450 3A4/CYP3A4 antibody. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 13 publications.


Images

Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921), expandable thumbnail
  • Immunoprecipitation - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921), expandable thumbnail
  • Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921), expandable thumbnail
  • Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921), expandable thumbnail

Publications

Key facts

Isotype

IgG

Host species

Rabbit

Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form

Liquid

Clonality

Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
IPWBIHC-P
Human
Tested
Tested
Tested

Tested
Tested

Species

Human

Dilution info

1/10 - 1/100

Notes

Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Tested
Tested

Species

Human

Dilution info

1/1000

Notes

For unpurified use at 1/10000 - 1/50000 dilution.

Tested
Tested

Species

Human

Dilution info

1/400

Notes

For unpurified use at 1/100 - 1/250 dilution.

Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Associated Products

Select an associated product type

3 products for Alternative Product

Target data

Function

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:20702771, PubMed:19965576, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:2732228, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:21576599, PubMed:21490593). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:14559847, PubMed:12865317). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:2732228, PubMed:15373842, PubMed:15764715, PubMed:22773874). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:2732228, PubMed:15373842, PubMed:15764715). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981).

Alternative names

Cytochrome P450 3A4, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, CYPIIIA3, CYPIIIA4, Cholesterol 25-hydroxylase, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Nifedipine oxidase, Quinine 3-monooxygenase, CYP3A4, CYP3A3

Recommended products

Rabbit Recombinant Monoclonal Cytochrome P450 3A4/CYP3A4 antibody. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 13 publications.

Key facts

Isotype

IgG

Form

Liquid

Clonality

Monoclonal

Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number

EPR6202

Purification technique

Affinity purification Protein A

Specificity

Cross-reactivity with other CYP3A family: ab124921 has high possibility of reacting with CYP3A7 based on our internal test.

Dissociation constant

2.63 x 10-10 M

Concentration
Loading...

Storage

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

Notes

Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Cytochrome P450 3A4 also known as CYP3A4 is an enzyme that plays an important role in the metabolism of many xenobiotics and endogenous compounds. It belongs to the cytochrome P450 superfamily and is a monooxygenase with a mass of approximately 57 kDa. CYP3A4 is primarily expressed in the liver and small intestine although it can be found in other tissues at lower levels. This enzyme catalyzes the oxidation of a wide variety of structurally unrelated compounds facilitating their excretion. Proadifen is a known inhibitor of CYP3A4 often used in research to study the effects of enzyme inhibition.

Biological function summary

CYP3A4 is involved in the metabolism of approximately half of all drugs used in clinical settings making it one of the most significant enzymes in drug metabolism. It does not usually function as part of a larger complex but acts individually on various substrates. Besides xenobiotic metabolism CYP3A4 also metabolizes steroids and other endogenous molecules. Climbazole an antifungal agent is a substrate for CYP3A4 demonstrating the enzyme's broad substrate specificity within the body's complex biochemical environment.

Pathways

CYP3A4 plays a central role in the drug metabolism pathway and the synthesis and metabolism of steroids. These pathways involve other cytochrome P450 enzymes including CYP2D6 and CYP2C9 which often work alongside CYP3A4 to metabolize compounds. The pathway's coordinated activities ensure proper drug metabolism and hormone regulation. Understanding the involvement of CYP3A4 in these pathways is critical for drug development and determining drug-drug interactions.

Associated diseases and disorders

CYP3A4 is associated with conditions such as drug-induced liver injury and variable drug responses. Alterations in CYP3A4 activity can lead to either toxic accumulations or reduced efficacy of medications. Additionally certain liver diseases can alter CYP3A4 expression further complicating treatment outcomes. The enzyme's interaction with other proteins like those of the cytochrome P450 family means that any dysfunctions can impact a wide range of metabolic processes and influence disease progression.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

7 product images

  • Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    This antibody fails to detect BOI in normal HepG2 cells which is positive reported by PMID 26089940 and 25141173

    All lanes: Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921) at 1/1000 dilution

    Lane 1: Human liver lysates at 20 µg

    Lane 2: HepG2 (Human hepatocellular carcinoma epithelial cell), Whole cell lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 57 kDa

    Observed band size: 50 kDa

  • Immunoprecipitation - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Immunoprecipitation - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    ab124921 (purified) at 1/20 dilution (1ug) immunoprecipitating Cytochrome P450 3A4/CYP3A4 in Human liver lysates.
    Lane 1: Human liver lysates 10ug
    Lane 2 (+): ab124921 & Human liver lysates
    Lane 3 (-): Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab124921 in Human liver lysates
    For western blotting, VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was at 1/1000 dilution.
    Blocking and diluting buffer: 5% NFDM/TBST.

    All lanes: Immunoprecipitation - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    Predicted band size: 57 kDa

  • Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    All lanes: Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921) at 1/10000 dilution

    All lanes: Human fetal liver lysate at 10 µg

    Secondary

    All lanes: HRP labelled goat anti rabbit at 1/2000 dilution

    Predicted band size: 57 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human liver tissue sections labeling Cytochrome P450 3A4/CYP3A4 with purified ab124921 at 1/400 dilution (0.35 µg/ml). Perform heat mediated antigen retrieval using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.

  • Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    HepG2 cells were incubated at 37°C for 48h with vehicle control (0 μM) and different concentrations of nicardipine hydrochloride (Nicardipine hydrochloride, L-type Ca2+ channel antagonist ab120531) in DMSO. Increased expression of Cytochrome P450 3A4/CYP3A4 (ab124921, unpurified) correlates with an increase in nicardipine hydrochloride concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab124921 (unpurified) at 1/10000 dilution and Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 at 1 μg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/10000 dilution and visualised using ECL development solution.

    All lanes: Western blot - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 57 kDa

    Exposure time: 20min

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    ab124921 (unpurified), at a 1/100 dilution, staining Cytochrome P450 3A4/CYP3A4 in paraffin embedded Human liver tissue by Immunohistochemistry.

  • OI-RD Scanning - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921), expandable thumbnail

    OI-RD Scanning - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (ab124921)

    We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
    Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com